The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Pharmacological approaches to methamphetamine dependence: a focused review
Open accessAbstract
Methamphetamine dependence is a serious worldwide public health problem with major medical, psychiatric, socioeconomic and legal consequences. Various neuronal mechanisms implicated in methamphetamine dependence have suggested several pharmacological approaches. A literature search from a range of electronic databases (PubMed, EMBASE, PsycInfo, the NIDA research monograph index and the reference list of clinicaltrials.gov) was conducted for the period from January 1985 to October 2009. There were no restrictions on the identification or inclusion of studies in terms of publication status, language and design type. A variety of medications have failed to show efficacy in clinical trials, including a dopamine partial agonist (aripiprazole), GABAergic agents (gabapentin) and serotonergic agents (SSRI, ondansetron, mirtazapine). Three double‐blind placebo‐controlled trials using modafinil, bupropion and naltrexone have shown positive results in reducing amphetamine or methamphetamine use. Two studies employing agonist replacement medications, one with d‐amphetamine and the other with methylphenidate, have also shown promise. Despite the lack of success in most studies to date, increasing efforts are being made to develop medications for the treatment of methamphetamine dependence and several promising agents are targets of further research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“however, research on the efficacy of pharmacotherapies to date has produced inconsistent results.22”
From Protocol for a systematic review of psychological treatment for methamphetamine use: An analysis of methamphetamine use and mental health symptom outcomes (2017) · cites this paper as [22]
In the citing paper
“A number of agents that modulate functional output of DA systems are effective first-line treatments for substance-use disorders [177].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [177]
Citations
Cites
Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667
Structural Abnormalities in the Brains of Human Subjects Who Use Methamphetamine
Thompson, P. M., Hayashi, K. M., Simon, S. L., Geaga, J. A., Hong, M., Sui, Y., Lee, J. Y., Toga, A. W., Ling, W. W., & London, E. D. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0713-04.2004 · Cited by 770
Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis
Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., & Grant, I. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9031-0 · Cited by 669
Drug addiction: the neurobiology of behaviour gone awry
Volkow, N. D., & Li, T. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1539 · Cited by 638
Involvement of the endocannabinoid system in drug addiction
Maldonado, R. J., Valverde, O., & Berrendero, F. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.008 · Cited by 601
Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain
Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G., Jayne, M. C., Hooker, J. M., Wong, C., et al. (2009) · JAMA · doi:10.1001/jama.2009.351 · Cited by 535
Cognitive enhancing effects of modafinil in healthy volunteers
Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J. H., & Sahakian, B. J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1250-8 · Cited by 518
The need for speed: an update on methamphetamine addiction
Barr, A. M., Panenka, W. J., MacEwan, G. W., Thornton, A. E., Lang, D. J., Honer, W. G., & Lecomte, T. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0635 · Cited by 441
The prevalence of psychotic symptoms among methamphetamine users
McKetin, R., McLaren, J., Lubman, D. I., & Hides, L. M. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01496.x · Cited by 393
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
Research works printed but not linked: 4
- Urschel HC, 2008, A controlled trial of flumazenil, gabapentin and hydroxyzine in treatment of methamphetamine dependence, Puerto Rico, 56
- Batki SL, 1999, Fluoxetine in methamphetamine dependence. A controlled trial: a preliminary analysis, Acapulco, 235
- Batki SL, 2002, Methamphetamine‐amlodipine interactions: preliminary analysis, Drug Alcohol Depend, 66, S12
- Batki SL, 2001, Amlodipine treatment of methamphetamine dependence, a controlled outpatient trial: preliminary analysis, Drug Alcohol Depend, 63, 12
Cited by
Sorted by citations
Items 201–243 of 243
High-Dose Poisoning, “Body Packers” Case That Ended in An Emergency: A Case Report
Çakır, A. (2021) · Open Access Journal of Toxicology · doi:10.19080/oajt.2021.05.555659 · Cited by 1
“half-life is on average 9-12 hours [12,13].”
Brain Histamine N-Methyltransferase as a Possible Target of Treatment for Methamphetamine Overdose
Kitanaka, J., Kitanaka, N., Hall, F. S., Uhl, G. R., & Takemura, M. (2016) · Drug Target Insights · doi:10.33393/dti.2016.1423 · Cited by 1
Sevarino, K. A., & Shelby, B. C. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch80 · Cited by 1
Moszczyńska, A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x1912211213145444 · Cited by 1
The Neurobiology of Methamphetamine Addiction and Ways to Reduce Misuse through VaccinesPreprint
Mathew, P. S., Kaur, K., Prasad, S., & Tian, M. Y. (2023) · Preprints.org · doi:10.20944/preprints202305.0045.v1
Effects of mitragynine on morphine and methamphetamine addiction in animal models of addiction
Meepong, R. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.33 · Cited by 1
Addiction to Amphetamines and Methamphetamines
Elkashef, A. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_16
Horton, D. B. (2012) · UKnowledge (University of Kentucky)
Snider, S. E. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/wt5e-6716
“While most research efforts have focused on targeting the bioamine receptors to develop pharmacotherapeutic 5 agents, for they are the direct mediators of methamphetamine's abuse-related effects (see below), those efforts have not been successful (Karila et al., 2010).”
BackgroundRecent advances in pharmacological management of substance use disorders
Kar, S. K., & Sharma, D. (2015) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/2231-0738.167505 · Cited by 1
“[76] Likewise, naltrexone appears to be a highly promising medication for amphetamine dependence.[77] Serotonergic agents such as SSRIs, mirtazapine, and ondansetron have been also explored, but convincing data is still required before their recommendation for clinical use.”
BackgroundA 51-Year-Old Man with Bipolar Disorder, HIV, Fatigue, Hypersomnolence, and Increased Appetite
Alexeenko, L., Patel, A. N., & Ungar, A. K. (2013) · Psychiatric Annals · doi:10.3928/00485713-20130906-03
Recent Publications on Medications and Pharmacy
Russett, F. (2011) · Hospital Pharmacy · doi:10.1310/hpj4606-458
Recent Publications on Medications and Pharmacy
Russett, F. (2012) · Hospital Pharmacy · doi:10.1310/hpj4705-401
REINFORCING, SUBJECTIVE, AND COGNITIVE EFFECTS OF METHAMPHETAMINE DURING D- AMPHETAMINE MAINTENANCE
Pike, E. (2013) · UKnowledge (University of Kentucky)
Farıdhosseını, F., Rajaei, A., Rasouli‐Azad, M., & Kordi, H. (2013)
The role of microglia in methamphetamine exposure
Canedo, T. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/0rv0-m465
Pharmacotherapies for Drug Addiction
Gipson, C. D., & Kalivas, P. W. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00357
Prenatal Methadone and Behavioral Sensitization Induced by Methamphetamine
Fan, L., & Tien, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800634-4.00059-7
Pharmacological Characterization of an Optimized Sigma Receptor Ligand
Seminerio, M. J. (2012) · doi:10.33915/etd.3561
“There have been a substantial amount of clinical trials conducted with drug candidates aimed at treating the addictive properties of methamphetamine; however at this time there are still no FDA approved pharmacotherapies for methamphetamine dependence (Karila et al., 2010).”
BackgroundMedizinische und psychosoziale Determinanten in Diagnostik und Therapie
Franke, A. G., Neumann, S., & Soyka, M. (2018) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-018-2445-9
Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?
Garzola, G. C. Q. (2020) · Revista Colombiana de Psicología · doi:10.15446/.v29n1.75930
“Different reviews (non-specialized in Gabapentin) have described the use of Gabapentin for treating these substances; specifically, reviews dealing with opioid consumption problems (Berlin, Butler, & Perloff, 2015; Olive, Cleva, Kalivas, & Malcolm, 2012; Rodriguez-Arias, Aguilar, & Minarro, 2015; Soyka & Mutschler, 20…”
BackgroundMetamfetamin Bağımlısı Bir Olgunun Yedam Modeli İle Tedavisi ve Takibi
Biçer, R., & Ögel, K. (2019) · Cyprus Turkish Journal of Psychiatry and Psychology · doi:10.35365/ctjpp.19.special1.18
Central nervous system stimulants and drugs that suppress appetite
Sequeira, R. P. (2012) · Side effects of drugs annual · doi:10.1016/b978-0-444-59499-0.00001-5
Betzler, F., & Köhler, S. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_67-1
Substance Use Disorder - New Research Perspectives in the Diagnosis, Treatment, and Prognosis
Sampedro-Piquero, P., Fernández, R. D. M., & Zancada-Menéndez, C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100838
Escudero, D. Q. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110784
“is exactly what even an acute dose of Meth does: due to its pharmacology, Meth forces the presynaptic neuron to flood the synapse with DA (Courtney and Ray, 2014; Karila et al., 2010; Pereira et al., 2006; Branch and Beckstead, 2012).”
Disorders Due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_26-1
Review of natural antioxidant plants to overcome the neurotoxic effects of methamphetamine
Arto, S. S., & Pangsibidang, R. C. A. (2024) · Pharmacy Education · doi:10.46542/pe.2024.246.5972
Ramshini, E., & Shabani, M. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.138033
The use of Modafinil on Methamphetamine withdrawal in mechanically ventilated patients
Akopyan, K., Engeleit, A., Nguyen, M. T., & Austin, A. (2025) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2025.102248
“The effects include euphoria which can last much longer than with the use of cocaine [4].”
Yerton, M., McCabe, C. J., Iles-Shih, M., Tsui, J. I., & Hallgren, K. A. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00593-8
“…medication that has demonstrated preliminary evidence of effectiveness for treating AT-StUDs (particularly methamphetamine use disorder) [4–6 , 19 ] and that has been conditionally recommended by clinical guidelines With no FDA-approved medications for AT-StUDs, additional efforts are needed…”
Addiction aux drogues stimulantes (cocaïne, méthamphétamine et nouveaux produits de synthèse)
Karila, L., & Lejoyeux, M. (2014) · Réanimation · doi:10.1007/s13546-014-0913-x
Self-citationKokain, Amphetamin und andere Stimulanzien
Koopmann, A., Fehr, C., & Kiefer, F. (2012) · Springer eBooks · doi:10.1007/978-3-642-19844-1_70
Kumar, J., Iezhitsa, I. N., & Agarwal, R. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00249-6 · Cited by 2
Li, X. J., Ding, J., Ma, X., & Zhang, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135677
Challenges in Anti-addiction Drug Development: Lost in Translation?
Li, J. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2026-0011
Chemsex et usage sexualisé de drogues : les problématiques toxicologiques
Fabre, M., & Mégarbane, B. (2026) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2026.07.006
Chung, A. K. K., Tang, S. W., Tse, C. Y., Law, J. K. C., Lee, C. K., Leung, W., Dong, Y. D., & Chan, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1892182
“Open-label studies of low dose risperidone have shown to reduce methamphetamine use among dependent individuals (Karila et al., 2010; Meredith et al., 2009).”
Aeinfar, M., Shakeri, J., Farnia, V., Alikhani, M., & Kamani, M. (2026) · Journal of Substance Use · doi:10.1080/14659891.2026.2741792
Swart, C. (2013) · Boloka Institutional Repository (North-west University)
Metadata
- Authors
- Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L.
- Affiliations
- Inserm (FR)
- Hadassah Medical Center (IL)
- San Francisco VA Medical Center (US)
- Corresponding author
- Karila, Laurent
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2010-05-10
- Volume
- 69
- Issue
- 6
- Pages
- 578-592
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC2883750
- OpenAlex
- W1747110054
- Cited by
- 242
- References
- 135
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 9 · 2023: 12 · 2022: 16 · 2021: 15 · 2020: 8 · 2019: 13 · 2018: 20 · 2017: 15 · 2016: 18 · 2015: 12 · 2014: 16 · 2013: 18 · 2012: 29
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (U10DA015815, R01DA016764, UG1DA015815)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- methamphetamine dependence, pharmacotherapy, partial dopamine agonist, aripiprazole, GABAergic agents, gabapentin, serotonergic agents, modafinil, bupropion, naltrexone, d-amphetamine, methylphenidate, drug addiction
- MeSH terms
- Animals, Calcium Channel Blockers, Humans, Immunotherapy, Methamphetamine, Narcotic Antagonists, Antipsychotic Agents, Neurotransmitter Agents, Amphetamine-Related Disorders, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
